Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance

BACKGROUND: While BMPR2 mutation strongly predisposes to pulmonary arterial hypertension (PAH), only 20% of mutation carriers develop clinical disease. This finding suggests that modifier genes contribute to FPAH clinical expression. Since modifiers are likely to be common alleles, this problem is n...

Descripción completa

Detalles Bibliográficos
Autores principales: West, James, Cogan, Joy, Geraci, Mark, Robinson, Linda, Newman, John, Phillips, John A, Lane, Kirk, Meyrick, Barbara, Loyd, Jim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561034/
https://www.ncbi.nlm.nih.gov/pubmed/18823550
http://dx.doi.org/10.1186/1755-8794-1-45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561034/
https://www.ncbi.nlm.nih.gov/pubmed/18823550
http://dx.doi.org/10.1186/1755-8794-1-45

Ejemplares similares